nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—chronic obstructive pulmonary disease	0.437	0.788	CbGaD
Gliclazide—ALB—chronic obstructive pulmonary disease	0.117	0.212	CbGaD
Gliclazide—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0469	0.187	CbGbCtD
Gliclazide—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0469	0.187	CbGbCtD
Gliclazide—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.039	0.155	CbGbCtD
Gliclazide—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.039	0.155	CbGbCtD
Gliclazide—ALB—Prednisone—chronic obstructive pulmonary disease	0.0304	0.121	CbGbCtD
Gliclazide—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0296	0.118	CbGbCtD
Gliclazide—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0197	0.0783	CbGbCtD
Gliclazide—VEGFA—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000408	0.253	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000408	0.253	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000398	0.247	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000398	0.247	CbGdCrCtD
Gliclazide—VEGFA—Endochondral Ossification—MMP9—chronic obstructive pulmonary disease	0.00017	0.00334	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000168	0.00332	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—SERPINA1—chronic obstructive pulmonary disease	0.000164	0.00323	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000159	0.00312	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000158	0.0031	CbGpPWpGaD
Gliclazide—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000157	0.00111	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.0011	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000156	0.0011	CcSEcCtD
Gliclazide—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000156	0.0011	CcSEcCtD
Gliclazide—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.0011	CcSEcCtD
Gliclazide—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000156	0.0011	CcSEcCtD
Gliclazide—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00109	CcSEcCtD
Gliclazide—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000154	0.00109	CcSEcCtD
Gliclazide—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000154	0.00109	CcSEcCtD
Gliclazide—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.00109	CcSEcCtD
Gliclazide—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000154	0.00109	CcSEcCtD
Gliclazide—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000154	0.00109	CcSEcCtD
Gliclazide—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00108	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00108	CcSEcCtD
Gliclazide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000153	0.00108	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000153	0.00301	CbGpPWpGaD
Gliclazide—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.00108	CcSEcCtD
Gliclazide—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00108	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000152	0.003	CbGpPWpGaD
Gliclazide—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00107	CcSEcCtD
Gliclazide—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.00106	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.00015	0.00296	CbGpPWpGaD
Gliclazide—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.00106	CcSEcCtD
Gliclazide—Infection—Formoterol—chronic obstructive pulmonary disease	0.00015	0.00106	CcSEcCtD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.00015	0.00294	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TGFB2—chronic obstructive pulmonary disease	0.000149	0.00294	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000149	0.00293	CbGpPWpGaD
Gliclazide—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.00105	CcSEcCtD
Gliclazide—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.00105	CcSEcCtD
Gliclazide—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.00105	CcSEcCtD
Gliclazide—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000149	0.00105	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—EGFR—chronic obstructive pulmonary disease	0.000149	0.00292	CbGpPWpGaD
Gliclazide—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.00105	CcSEcCtD
Gliclazide—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000148	0.00105	CcSEcCtD
Gliclazide—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000148	0.00105	CcSEcCtD
Gliclazide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000148	0.00104	CcSEcCtD
Gliclazide—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000148	0.0029	CbGpPWpGaD
Gliclazide—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000147	0.00104	CcSEcCtD
Gliclazide—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.00104	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MMP1—chronic obstructive pulmonary disease	0.000147	0.00289	CbGpPWpGaD
Gliclazide—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00104	CcSEcCtD
Gliclazide—Infection—Montelukast—chronic obstructive pulmonary disease	0.000147	0.00104	CcSEcCtD
Gliclazide—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.00104	CcSEcCtD
Gliclazide—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000147	0.00104	CcSEcCtD
Gliclazide—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000146	0.00103	CcSEcCtD
Gliclazide—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.00103	CcSEcCtD
Gliclazide—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000145	0.00102	CcSEcCtD
Gliclazide—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000145	0.00102	CcSEcCtD
Gliclazide—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00102	CcSEcCtD
Gliclazide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000144	0.00101	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—chronic obstructive pulmonary disease	0.000142	0.0028	CbGpPWpGaD
Gliclazide—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.001	CcSEcCtD
Gliclazide—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000996	CcSEcCtD
Gliclazide—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000996	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NOS3—chronic obstructive pulmonary disease	0.00014	0.00276	CbGpPWpGaD
Gliclazide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00014	0.000991	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—TGFB1—chronic obstructive pulmonary disease	0.00014	0.00276	CbGpPWpGaD
Gliclazide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.000987	CcSEcCtD
Gliclazide—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000986	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000139	0.00274	CbGpPWpGaD
Gliclazide—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.000982	CcSEcCtD
Gliclazide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000978	CcSEcCtD
Gliclazide—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000138	0.000973	CcSEcCtD
Gliclazide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000973	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000138	0.000971	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000138	0.000971	CcSEcCtD
Gliclazide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000964	CcSEcCtD
Gliclazide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000964	CcSEcCtD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000136	0.00268	CbGpPWpGaD
Gliclazide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000136	0.000958	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000135	0.000951	CcSEcCtD
Gliclazide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000135	0.00095	CcSEcCtD
Gliclazide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.00095	CcSEcCtD
Gliclazide—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000135	0.00265	CbGpPWpGaD
Gliclazide—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000134	0.000948	CcSEcCtD
Gliclazide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.000948	CcSEcCtD
Gliclazide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000944	CcSEcCtD
Gliclazide—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.00094	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RAPGEF3—chronic obstructive pulmonary disease	0.000133	0.00262	CbGpPWpGaD
Gliclazide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000133	0.000938	CcSEcCtD
Gliclazide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000133	0.000938	CcSEcCtD
Gliclazide—VEGFA—Differentiation Pathway—IL6—chronic obstructive pulmonary disease	0.000133	0.00261	CbGpPWpGaD
Gliclazide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000133	0.000937	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—NOS3—chronic obstructive pulmonary disease	0.000133	0.00261	CbGpPWpGaD
Gliclazide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000132	0.000934	CcSEcCtD
Gliclazide—Injury—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000929	CcSEcCtD
Gliclazide—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000131	0.000928	CcSEcCtD
Gliclazide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000131	0.000926	CcSEcCtD
Gliclazide—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.000924	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00013	0.00092	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00013	0.00092	CcSEcCtD
Gliclazide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00013	0.000919	CcSEcCtD
Gliclazide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00013	0.000919	CcSEcCtD
Gliclazide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00013	0.000919	CcSEcCtD
Gliclazide—ABCC8—Metabolism—APIP—chronic obstructive pulmonary disease	0.00013	0.00256	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000917	CcSEcCtD
Gliclazide—Pain—Formoterol—chronic obstructive pulmonary disease	0.000129	0.000912	CcSEcCtD
Gliclazide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000129	0.000912	CcSEcCtD
Gliclazide—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000129	0.000912	CcSEcCtD
Gliclazide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000129	0.000912	CcSEcCtD
Gliclazide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.00091	CcSEcCtD
Gliclazide—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000908	CcSEcCtD
Gliclazide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000904	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000128	0.000901	CcSEcCtD
Gliclazide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000127	0.0009	CcSEcCtD
Gliclazide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000897	CcSEcCtD
Gliclazide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000895	CcSEcCtD
Gliclazide—Pain—Montelukast—chronic obstructive pulmonary disease	0.000126	0.000893	CcSEcCtD
Gliclazide—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000892	CcSEcCtD
Gliclazide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000126	0.00089	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—APIP—chronic obstructive pulmonary disease	0.000126	0.00248	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000126	0.00247	CbGpPWpGaD
Gliclazide—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000887	CcSEcCtD
Gliclazide—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000887	CcSEcCtD
Gliclazide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.000886	CcSEcCtD
Gliclazide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000125	0.000883	CcSEcCtD
Gliclazide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000125	0.000882	CcSEcCtD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP9—chronic obstructive pulmonary disease	0.000125	0.00246	CbGpPWpGaD
Gliclazide—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.00088	CcSEcCtD
Gliclazide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.000878	CcSEcCtD
Gliclazide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000124	0.000878	CcSEcCtD
Gliclazide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000124	0.000877	CcSEcCtD
Gliclazide—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000875	CcSEcCtD
Gliclazide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000124	0.000873	CcSEcCtD
Gliclazide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.000872	CcSEcCtD
Gliclazide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000123	0.000872	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.000869	CcSEcCtD
Gliclazide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.000868	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—CRP—chronic obstructive pulmonary disease	0.000122	0.00241	CbGpPWpGaD
Gliclazide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.000861	CcSEcCtD
Gliclazide—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.000861	CcSEcCtD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000121	0.00239	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000121	0.000854	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000853	CcSEcCtD
Gliclazide—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000853	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—GSTP1—chronic obstructive pulmonary disease	0.00012	0.00237	CbGpPWpGaD
Gliclazide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00012	0.000847	CcSEcCtD
Gliclazide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00012	0.000847	CcSEcCtD
Gliclazide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.000843	CcSEcCtD
Gliclazide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.000843	CcSEcCtD
Gliclazide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000119	0.000843	CcSEcCtD
Gliclazide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000119	0.000843	CcSEcCtD
Gliclazide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000119	0.00084	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000118	0.00233	CbGpPWpGaD
Gliclazide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000118	0.000833	CcSEcCtD
Gliclazide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000118	0.000832	CcSEcCtD
Gliclazide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000118	0.000832	CcSEcCtD
Gliclazide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000117	0.000829	CcSEcCtD
Gliclazide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.000829	CcSEcCtD
Gliclazide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000117	0.000827	CcSEcCtD
Gliclazide—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000827	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	0.000117	0.00231	CbGpPWpGaD
Gliclazide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000117	0.000825	CcSEcCtD
Gliclazide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000117	0.000825	CcSEcCtD
Gliclazide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.000823	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000115	0.00226	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL6—chronic obstructive pulmonary disease	0.000114	0.00225	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000114	0.00224	CbGpPWpGaD
Gliclazide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.0008	CcSEcCtD
Gliclazide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.000796	CcSEcCtD
Gliclazide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.000796	CcSEcCtD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	0.000112	0.0022	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000111	0.00219	CbGpPWpGaD
Gliclazide—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000111	0.000785	CcSEcCtD
Gliclazide—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000111	0.000785	CcSEcCtD
Gliclazide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000111	0.000785	CcSEcCtD
Gliclazide—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.000783	CcSEcCtD
Gliclazide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000782	CcSEcCtD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000111	0.00218	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.00011	0.00217	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00011	0.00216	CbGpPWpGaD
Gliclazide—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000109	0.000769	CcSEcCtD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.00214	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000109	0.00214	CbGpPWpGaD
Gliclazide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000108	0.000765	CcSEcCtD
Gliclazide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000108	0.000765	CcSEcCtD
Gliclazide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.00211	CbGpPWpGaD
Gliclazide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000107	0.000754	CcSEcCtD
Gliclazide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000107	0.000754	CcSEcCtD
Gliclazide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000106	0.000749	CcSEcCtD
Gliclazide—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000743	CcSEcCtD
Gliclazide—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.000742	CcSEcCtD
Gliclazide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000105	0.000739	CcSEcCtD
Gliclazide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000103	0.000729	CcSEcCtD
Gliclazide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000103	0.000729	CcSEcCtD
Gliclazide—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000726	CcSEcCtD
Gliclazide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.000722	CcSEcCtD
Gliclazide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000101	0.000714	CcSEcCtD
Gliclazide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000712	CcSEcCtD
Gliclazide—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.0001	0.000707	CcSEcCtD
Gliclazide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	9.98e-05	0.000705	CcSEcCtD
Gliclazide—Dizziness—Formoterol—chronic obstructive pulmonary disease	9.98e-05	0.000705	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—CRP—chronic obstructive pulmonary disease	9.95e-05	0.00196	CbGpPWpGaD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.91e-05	0.00195	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	9.79e-05	0.00193	CbGpPWpGaD
Gliclazide—Dizziness—Montelukast—chronic obstructive pulmonary disease	9.78e-05	0.00069	CcSEcCtD
Gliclazide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.78e-05	0.00192	CbGpPWpGaD
Gliclazide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	9.75e-05	0.000689	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—TGFB2—chronic obstructive pulmonary disease	9.67e-05	0.0019	CbGpPWpGaD
Gliclazide—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	9.62e-05	0.000679	CcSEcCtD
Gliclazide—Vomiting—Formoterol—chronic obstructive pulmonary disease	9.6e-05	0.000678	CcSEcCtD
Gliclazide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	9.6e-05	0.000678	CcSEcCtD
Gliclazide—Rash—Arformoterol—chronic obstructive pulmonary disease	9.52e-05	0.000672	CcSEcCtD
Gliclazide—Rash—Formoterol—chronic obstructive pulmonary disease	9.52e-05	0.000672	CcSEcCtD
Gliclazide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	9.51e-05	0.000671	CcSEcCtD
Gliclazide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	9.51e-05	0.000671	CcSEcCtD
Gliclazide—Weight increased—Prednisone—chronic obstructive pulmonary disease	9.51e-05	0.000671	CcSEcCtD
Gliclazide—Headache—Arformoterol—chronic obstructive pulmonary disease	9.46e-05	0.000668	CcSEcCtD
Gliclazide—Headache—Formoterol—chronic obstructive pulmonary disease	9.46e-05	0.000668	CcSEcCtD
Gliclazide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	9.43e-05	0.000666	CcSEcCtD
Gliclazide—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	9.42e-05	0.000665	CcSEcCtD
Gliclazide—Vomiting—Montelukast—chronic obstructive pulmonary disease	9.4e-05	0.000664	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—SERPINE1—chronic obstructive pulmonary disease	9.39e-05	0.00185	CbGpPWpGaD
Gliclazide—Rash—Montelukast—chronic obstructive pulmonary disease	9.32e-05	0.000658	CcSEcCtD
Gliclazide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	9.31e-05	0.000658	CcSEcCtD
Gliclazide—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	9.29e-05	0.000656	CcSEcCtD
Gliclazide—Depression—Prednisone—chronic obstructive pulmonary disease	9.29e-05	0.000656	CcSEcCtD
Gliclazide—Headache—Montelukast—chronic obstructive pulmonary disease	9.26e-05	0.000654	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	9.21e-05	0.00181	CbGpPWpGaD
Gliclazide—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	9.18e-05	0.000648	CcSEcCtD
Gliclazide—Angioedema—Prednisolone—chronic obstructive pulmonary disease	9.15e-05	0.000646	CcSEcCtD
Gliclazide—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	9.13e-05	0.000645	CcSEcCtD
Gliclazide—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	9.13e-05	0.000645	CcSEcCtD
Gliclazide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	9.06e-05	0.00064	CcSEcCtD
Gliclazide—Malaise—Prednisolone—chronic obstructive pulmonary disease	9.03e-05	0.000638	CcSEcCtD
Gliclazide—Rash—Salbutamol—chronic obstructive pulmonary disease	8.99e-05	0.000635	CcSEcCtD
Gliclazide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	8.98e-05	0.000634	CcSEcCtD
Gliclazide—Nausea—Arformoterol—chronic obstructive pulmonary disease	8.97e-05	0.000633	CcSEcCtD
Gliclazide—Nausea—Formoterol—chronic obstructive pulmonary disease	8.97e-05	0.000633	CcSEcCtD
Gliclazide—Headache—Salbutamol—chronic obstructive pulmonary disease	8.93e-05	0.000631	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	8.87e-05	0.00175	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	8.84e-05	0.00174	CbGpPWpGaD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.81e-05	0.00173	CbGpPWpGaD
Gliclazide—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	8.8e-05	0.000622	CcSEcCtD
Gliclazide—Nausea—Montelukast—chronic obstructive pulmonary disease	8.78e-05	0.00062	CcSEcCtD
Gliclazide—Convulsion—Prednisolone—chronic obstructive pulmonary disease	8.68e-05	0.000613	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—HDAC2—chronic obstructive pulmonary disease	8.67e-05	0.00171	CbGpPWpGaD
Gliclazide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	8.65e-05	0.000611	CcSEcCtD
Gliclazide—ABCC8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.61e-05	0.0017	CbGpPWpGaD
Gliclazide—Bradycardia—Prednisone—chronic obstructive pulmonary disease	8.51e-05	0.000601	CcSEcCtD
Gliclazide—Nausea—Salbutamol—chronic obstructive pulmonary disease	8.47e-05	0.000598	CcSEcCtD
Gliclazide—Discomfort—Prednisolone—chronic obstructive pulmonary disease	8.43e-05	0.000595	CcSEcCtD
Gliclazide—ABCC8—Metabolism—GC—chronic obstructive pulmonary disease	8.38e-05	0.00165	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.35e-05	0.00164	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	8.23e-05	0.00162	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	8.22e-05	0.00162	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GC—chronic obstructive pulmonary disease	8.13e-05	0.0016	CbGpPWpGaD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.03e-05	0.00158	CbGpPWpGaD
Gliclazide—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	7.98e-05	0.000563	CcSEcCtD
Gliclazide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	7.9e-05	0.000558	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	7.9e-05	0.00156	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	7.84e-05	0.00154	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PLAUR—chronic obstructive pulmonary disease	7.82e-05	0.00154	CbGpPWpGaD
Gliclazide—Eye disorder—Prednisone—chronic obstructive pulmonary disease	7.81e-05	0.000552	CcSEcCtD
Gliclazide—ABCC8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.79e-05	0.00153	CbGpPWpGaD
Gliclazide—Flushing—Prednisone—chronic obstructive pulmonary disease	7.76e-05	0.000548	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.75e-05	0.00152	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.66e-05	0.00151	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—SERPINE1—chronic obstructive pulmonary disease	7.64e-05	0.0015	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	7.63e-05	0.0015	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL1B—chronic obstructive pulmonary disease	7.63e-05	0.0015	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.55e-05	0.00149	CbGpPWpGaD
Gliclazide—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	7.47e-05	0.000527	CcSEcCtD
Gliclazide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	7.39e-05	0.000522	CcSEcCtD
Gliclazide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	7.34e-05	0.000518	CcSEcCtD
Gliclazide—Mental disorder—Prednisone—chronic obstructive pulmonary disease	7.33e-05	0.000517	CcSEcCtD
Gliclazide—Erythema—Prednisone—chronic obstructive pulmonary disease	7.28e-05	0.000514	CcSEcCtD
Gliclazide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	7.28e-05	0.000514	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.07e-05	0.00139	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—chronic obstructive pulmonary disease	7e-05	0.00138	CbGpPWpGaD
Gliclazide—Pain—Prednisolone—chronic obstructive pulmonary disease	6.99e-05	0.000494	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.98e-05	0.00137	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EGFR—chronic obstructive pulmonary disease	6.91e-05	0.00136	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	6.85e-05	0.00135	CbGpPWpGaD
Gliclazide—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	6.75e-05	0.000477	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	6.74e-05	0.000476	CcSEcCtD
Gliclazide—Anaemia—Prednisone—chronic obstructive pulmonary disease	6.73e-05	0.000475	CcSEcCtD
Gliclazide—Agitation—Prednisone—chronic obstructive pulmonary disease	6.69e-05	0.000472	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	6.68e-05	0.00132	CbGpPWpGaD
Gliclazide—Angioedema—Prednisone—chronic obstructive pulmonary disease	6.65e-05	0.00047	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	6.62e-05	0.0013	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—IL6—chronic obstructive pulmonary disease	6.6e-05	0.0013	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	6.58e-05	0.0013	CbGpPWpGaD
Gliclazide—Malaise—Prednisone—chronic obstructive pulmonary disease	6.56e-05	0.000464	CcSEcCtD
Gliclazide—ALB—Platelet degranulation—SERPINE1—chronic obstructive pulmonary disease	6.55e-05	0.00129	CbGpPWpGaD
Gliclazide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	6.5e-05	0.000459	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.44e-05	0.00127	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	6.41e-05	0.00126	CbGpPWpGaD
Gliclazide—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	6.4e-05	0.000452	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.35e-05	0.00125	CbGpPWpGaD
Gliclazide—Convulsion—Prednisone—chronic obstructive pulmonary disease	6.31e-05	0.000445	CcSEcCtD
Gliclazide—Hypertension—Prednisone—chronic obstructive pulmonary disease	6.28e-05	0.000444	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—chronic obstructive pulmonary disease	6.24e-05	0.00123	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL1B—chronic obstructive pulmonary disease	6.21e-05	0.00122	CbGpPWpGaD
Gliclazide—Arthralgia—Prednisone—chronic obstructive pulmonary disease	6.2e-05	0.000438	CcSEcCtD
Gliclazide—Myalgia—Prednisone—chronic obstructive pulmonary disease	6.2e-05	0.000438	CcSEcCtD
Gliclazide—Anxiety—Prednisone—chronic obstructive pulmonary disease	6.18e-05	0.000436	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	6.15e-05	0.000435	CcSEcCtD
Gliclazide—Discomfort—Prednisone—chronic obstructive pulmonary disease	6.12e-05	0.000432	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	6.07e-05	0.00119	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	6.07e-05	0.00119	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CXCL8—chronic obstructive pulmonary disease	6.05e-05	0.00119	CbGpPWpGaD
Gliclazide—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	6.02e-05	0.000425	CcSEcCtD
Gliclazide—Infection—Prednisone—chronic obstructive pulmonary disease	5.9e-05	0.000417	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.87e-05	0.00116	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	5.84e-05	0.00115	CbGpPWpGaD
Gliclazide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	5.83e-05	0.000411	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	5.8e-05	0.00114	CbGpPWpGaD
Gliclazide—Tachycardia—Prednisone—chronic obstructive pulmonary disease	5.8e-05	0.000409	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.79e-05	0.00114	CbGpPWpGaD
Gliclazide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	5.77e-05	0.000407	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—EGFR—chronic obstructive pulmonary disease	5.75e-05	0.00113	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	5.74e-05	0.000406	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	5.73e-05	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MMP1—chronic obstructive pulmonary disease	5.59e-05	0.0011	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—chronic obstructive pulmonary disease	5.53e-05	0.00109	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—LEP—chronic obstructive pulmonary disease	5.51e-05	0.00108	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PLAU—chronic obstructive pulmonary disease	5.48e-05	0.00108	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	5.45e-05	0.00107	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.45e-05	0.00107	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	5.41e-05	0.000382	CcSEcCtD
Gliclazide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	5.41e-05	0.000382	CcSEcCtD
Gliclazide—Insomnia—Prednisone—chronic obstructive pulmonary disease	5.37e-05	0.000379	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.37e-05	0.00106	CbGpPWpGaD
Gliclazide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	5.33e-05	0.000377	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.3e-05	0.00104	CbGpPWpGaD
Gliclazide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	5.23e-05	0.000369	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	5.2e-05	0.00102	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	5.17e-05	0.00102	CbGpPWpGaD
Gliclazide—Rash—Prednisolone—chronic obstructive pulmonary disease	5.16e-05	0.000364	CcSEcCtD
Gliclazide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	5.15e-05	0.000364	CcSEcCtD
Gliclazide—Fatigue—Prednisone—chronic obstructive pulmonary disease	5.12e-05	0.000362	CcSEcCtD
Gliclazide—Headache—Prednisolone—chronic obstructive pulmonary disease	5.12e-05	0.000362	CcSEcCtD
Gliclazide—Constipation—Prednisone—chronic obstructive pulmonary disease	5.08e-05	0.000359	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—NOS2—chronic obstructive pulmonary disease	5.04e-05	0.000992	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.99e-05	0.000982	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.97e-05	0.000977	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.94e-05	0.000971	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	4.93e-05	0.00097	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.9e-05	0.000964	CbGpPWpGaD
Gliclazide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	4.9e-05	0.000346	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.87e-05	0.000958	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	4.86e-05	0.000343	CcSEcCtD
Gliclazide—Nausea—Prednisolone—chronic obstructive pulmonary disease	4.86e-05	0.000343	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.83e-05	0.000951	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	4.81e-05	0.000946	CbGpPWpGaD
Gliclazide—Urticaria—Prednisone—chronic obstructive pulmonary disease	4.72e-05	0.000333	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	4.7e-05	0.000332	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	4.7e-05	0.000332	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.68e-05	0.000921	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP9—chronic obstructive pulmonary disease	4.64e-05	0.000914	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.61e-05	0.000908	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.58e-05	0.000901	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GCLC—chronic obstructive pulmonary disease	4.53e-05	0.000891	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—chronic obstructive pulmonary disease	4.5e-05	0.000886	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TNF—chronic obstructive pulmonary disease	4.5e-05	0.000886	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.5e-05	0.000886	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	4.47e-05	0.000879	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.44e-05	0.000874	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.44e-05	0.000873	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GCLC—chronic obstructive pulmonary disease	4.39e-05	0.000864	CbGpPWpGaD
Gliclazide—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	4.38e-05	0.000309	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—chronic obstructive pulmonary disease	4.29e-05	0.000844	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.27e-05	0.00084	CbGpPWpGaD
Gliclazide—Asthenia—Prednisone—chronic obstructive pulmonary disease	4.26e-05	0.000301	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	4.24e-05	0.000835	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ALB—chronic obstructive pulmonary disease	4.23e-05	0.000833	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.21e-05	0.000828	CbGpPWpGaD
Gliclazide—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.2e-05	0.000297	CcSEcCtD
Gliclazide—ALB—Metabolism—APIP—chronic obstructive pulmonary disease	4.19e-05	0.000825	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	4.13e-05	0.000814	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CTGF—chronic obstructive pulmonary disease	4.13e-05	0.000813	CbGpPWpGaD
Gliclazide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.07e-05	0.000287	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—NOS3—chronic obstructive pulmonary disease	4.05e-05	0.000797	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.02e-05	0.000791	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.01e-05	0.00079	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CTGF—chronic obstructive pulmonary disease	4e-05	0.000788	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—chronic obstructive pulmonary disease	3.97e-05	0.000781	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	3.94e-05	0.000775	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	3.93e-05	0.000774	CbGpPWpGaD
Gliclazide—Dizziness—Prednisone—chronic obstructive pulmonary disease	3.93e-05	0.000277	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.8e-05	0.000749	CbGpPWpGaD
Gliclazide—Vomiting—Prednisone—chronic obstructive pulmonary disease	3.78e-05	0.000267	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	3.76e-05	0.000741	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EGFR—chronic obstructive pulmonary disease	3.75e-05	0.000738	CbGpPWpGaD
Gliclazide—Rash—Prednisone—chronic obstructive pulmonary disease	3.75e-05	0.000264	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	3.74e-05	0.000264	CcSEcCtD
Gliclazide—Headache—Prednisone—chronic obstructive pulmonary disease	3.72e-05	0.000263	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—TP53—chronic obstructive pulmonary disease	3.71e-05	0.00073	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.69e-05	0.000726	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	3.63e-05	0.000715	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	3.58e-05	0.000704	CbGpPWpGaD
Gliclazide—Nausea—Prednisone—chronic obstructive pulmonary disease	3.53e-05	0.000249	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.43e-05	0.000675	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	3.41e-05	0.000671	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—chronic obstructive pulmonary disease	3.4e-05	0.000668	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—chronic obstructive pulmonary disease	3.31e-05	0.000652	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.17e-05	0.000625	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.13e-05	0.000616	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.08e-05	0.000606	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	3.06e-05	0.000602	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.03e-05	0.000597	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.99e-05	0.000588	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.94e-05	0.000579	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.92e-05	0.000574	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	2.9e-05	0.000572	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	2.89e-05	0.000568	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—chronic obstructive pulmonary disease	2.88e-05	0.000567	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.83e-05	0.000556	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.78e-05	0.000547	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.76e-05	0.000544	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	2.76e-05	0.000543	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.75e-05	0.000542	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.73e-05	0.000538	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	2.73e-05	0.000537	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GC—chronic obstructive pulmonary disease	2.7e-05	0.000532	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.68e-05	0.000528	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.68e-05	0.000528	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—chronic obstructive pulmonary disease	2.68e-05	0.000527	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—chronic obstructive pulmonary disease	2.68e-05	0.000527	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—chronic obstructive pulmonary disease	2.55e-05	0.000502	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.52e-05	0.000496	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.51e-05	0.000494	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.49e-05	0.000491	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.47e-05	0.000487	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.45e-05	0.000482	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	2.43e-05	0.000477	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.27e-05	0.000447	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.26e-05	0.000444	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.25e-05	0.000444	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.25e-05	0.000444	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.21e-05	0.000435	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—chronic obstructive pulmonary disease	2.2e-05	0.000434	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.15e-05	0.000424	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—chronic obstructive pulmonary disease	2.06e-05	0.000405	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.06e-05	0.000405	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.05e-05	0.000403	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2e-05	0.000394	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	2e-05	0.000393	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	1.97e-05	0.000388	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.97e-05	0.000388	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	1.94e-05	0.000381	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—chronic obstructive pulmonary disease	1.88e-05	0.00037	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.83e-05	0.000361	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.83e-05	0.000361	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—chronic obstructive pulmonary disease	1.82e-05	0.000359	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NOS3—chronic obstructive pulmonary disease	1.8e-05	0.000354	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.8e-05	0.000354	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.78e-05	0.00035	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NOS3—chronic obstructive pulmonary disease	1.74e-05	0.000343	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.64e-05	0.000322	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	1.5e-05	0.000295	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.48e-05	0.000291	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	1.46e-05	0.000287	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.44e-05	0.000283	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	1.43e-05	0.000281	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.37e-05	0.00027	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	1.33e-05	0.000262	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.33e-05	0.000261	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.31e-05	0.000258	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.23e-05	0.000241	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.22e-05	0.00024	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.22e-05	0.00024	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.21e-05	0.000238	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.2e-05	0.000235	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.19e-05	0.000235	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.11e-05	0.000219	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.1e-05	0.000217	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.1e-05	0.000217	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.09e-05	0.000214	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.03e-05	0.000203	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.02e-05	0.000201	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.01e-05	0.000199	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1e-05	0.000198	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.45e-06	0.000186	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.4e-06	0.000185	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.19e-06	0.000181	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.08e-06	0.000179	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.06e-06	0.000178	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.91e-06	0.000175	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.9e-06	0.000175	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.44e-06	0.000166	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.38e-06	0.000165	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.26e-06	0.000163	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8e-06	0.000157	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	7.78e-06	0.000153	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.7e-06	0.000151	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.48e-06	0.000147	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.3e-06	0.000144	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.84e-06	0.000135	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	5.8e-06	0.000114	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	5.44e-06	0.000107	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	5.2e-06	0.000102	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	4.96e-06	9.76e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	4.74e-06	9.34e-05	CbGpPWpGaD
